[Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002]

Bull Cancer. 2002 Jun;89(6):567-9.
[Article in French]
No abstract available

Publication types

  • Congress

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Dermatofibrosarcoma / drug therapy
  • Florida
  • Gastrointestinal Neoplasms / drug therapy
  • Gastrointestinal Neoplasms / genetics
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Piperazines / therapeutic use*
  • Protein-Tyrosine Kinases / therapeutic use*
  • Proto-Oncogene Proteins c-kit / metabolism
  • Pyrimidines / therapeutic use*
  • Sarcoma / drug therapy
  • Sarcoma / genetics
  • Skin Neoplasms / drug therapy

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-kit